In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil
about
Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutantsMechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavirTwo-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions presentLong-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48.Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B.Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.Investigational pharmacologic treatment for liver disease.Hepatitis B virus resistance to lamivudine and its clinical implications.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Adefovir dipivoxil in the treatment of chronic hepatitis B.The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitroPotential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo.Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance.Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates.HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.Molecular methods in the diagnosis and management of chronic hepatitis B.In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across GenotypesIn vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection.The hepatitis B e antigen suppresses IL-1β-mediated NF-κB activation in hepatocytes.Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection modelThe rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.Understanding the molecular basis of HBV drug resistance by molecular modeling.Inhibition of hepatitis B virus polymerase by entecavir.Synthesis, structural characterization and biological evaluation of 4'-C-methyl- and phenyl-dioxolane pyrimidine and purine nucleosides.Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy.Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites.Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.Short communication cellular pharmacology of 9-(beta-D-1,3-dioxolan-4-yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes.
P2860
Q24563991-DBB61A45-1AE5-40A0-B2A5-AE606E1F1E2EQ28748931-C9EF1FC0-799B-4E9D-A9E0-CB7078C3BC4AQ33267067-20571087-22F2-49C6-BA99-D0242783D046Q33417353-9942C04E-4A22-4A65-B90B-765EB089555EQ33549555-6C4DE9DD-A3F8-470B-AD73-D82E8DDC73D4Q33676340-1BF5DE68-9FEF-45C3-8DC2-86DA2E06669CQ33807256-AEF5483E-6625-4B2C-ABA4-28E242D122A6Q33826784-515863C3-5B96-4DBF-B7D4-304CD9544B71Q34841865-528F55D8-2D12-4844-962E-C801F9927CE6Q35007583-D848EE01-EADB-4241-AB9D-DF36212E2F83Q35558801-4CBEF6F4-E3CB-4144-8916-1AB590664745Q35678267-B3395662-36D0-4B6C-B394-E241E29A9D7BQ35879053-E35832E9-CDEF-4EA3-BD72-3CB6F69C9330Q35917125-005E0309-676D-4C56-88D1-3C401C413A41Q36607389-F90B48E6-2939-43D4-9091-6FA6FE735120Q37074608-FFAED193-BDEA-46F8-ABBD-8966CB1B528FQ37158625-2B28D817-65A3-4A7A-98C0-EDE039BF6897Q37247742-DBFF5E15-607D-42EB-B4F4-6FCA586990A4Q37708188-DC95DAC4-5065-4B03-9FE6-B54E7176B3EFQ37801940-BFF86D5B-42AF-4C13-8B2E-5EBBEA388DDDQ38736225-361E163F-50F9-4CA8-A701-E45B438836EEQ39328819-1AA06FED-4F2A-4C63-BDA0-411C253C82BEQ39474523-EFB02A2B-CFAD-4B6E-972C-D325E062A432Q39755479-1528E6ED-A621-48F8-9F86-E554F8B2A092Q39876916-D7E9E794-AE46-4D7A-B861-A6022030A232Q40012022-48EEDE32-7E29-40D6-BCAD-9AE3F88B5B51Q40052006-62371832-DC28-4A2C-9D77-C13C1FBF50CAQ40176633-0D68ACF5-98A3-43EF-912E-5E7B283128FDQ40586859-63CBC982-F6FE-4C1E-9FB1-3648B39FA55BQ43702187-352BAD6B-9C0D-47B2-937C-6702857DB17BQ45363333-6652DCC2-8503-4569-A2B0-83C52BF3B736Q45388069-5C39E27F-DECD-4FEE-BE38-109003F245A2Q45388432-D3EEA032-753E-4D2F-8379-24F0FFC16243Q46718131-EC448060-7AAE-470C-A239-ED087CB82357
P2860
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In vitro susceptibilities of w ...... -beta-L-arabinofuranosyluracil
@ast
In vitro susceptibilities of w ...... -beta-L-arabinofuranosyluracil
@en
In vitro susceptibilities of w ...... -beta-L-arabinofuranosyluracil
@nl
type
label
In vitro susceptibilities of w ...... -beta-L-arabinofuranosyluracil
@ast
In vitro susceptibilities of w ...... -beta-L-arabinofuranosyluracil
@en
In vitro susceptibilities of w ...... -beta-L-arabinofuranosyluracil
@nl
prefLabel
In vitro susceptibilities of w ...... -beta-L-arabinofuranosyluracil
@ast
In vitro susceptibilities of w ...... -beta-L-arabinofuranosyluracil
@en
In vitro susceptibilities of w ...... -beta-L-arabinofuranosyluracil
@nl
P2093
P2860
P1476
In vitro susceptibilities of w ...... -beta-L-arabinofuranosyluracil
@en
P2093
C Trautwein
S Locarnini
P2860
P304
P356
10.1128/AAC.45.9.2495-2501.2001
P407
P577
2001-09-01T00:00:00Z